We have been lucky enough to enjoy some excellent media and dissemination over the past 3 ½ years. Our REDDSTAR project has the potential to leave a substantial and lasting impact on stem cell research, cell therapies, patient outcome, industrial technologies and on the EU research landscape.
Our team has been committed to communicating the project concept, progress and results to a range of audiences, including life science researchers, clinicians, drug development companies, the general public, the media, advocacy and patient representative groups, other relevant EU projects and young people.
A dedicated dissemination and exploitation work package has addressed this aim and we have reached over 230 stories, including nine publications, television appearances, public and patients meetings and schools’ science engagement activities. Below, please read about some of our highlights.
On 22nd April 2014, the REDDSTAR consortium gathered in Paris to evaluate the project’s preclinical studies on SSC treatment of diabetic complications. The advisory board concluded that a phase 1b trial could be done with diabetic ulcers and topical administration of CD362+SSC (trademarked by Orbsen Therapeutics as Orbcel-M), in combination with Excellagen. Read more here.
More than 100 delegates attended the public gathering ‘Diabetes- it’s complicated’ last evening in Aras Moyola at National University of Ireland (NUI) in Galway. Six multidisciplinary talks were delivered on a variety of topics including what makes Galway a great place for cell therapy and for advancing treatments in diabetes, diabetic eye disease, what are stem cells and why they are medically interesting, impaired bone fracture repair in people with diabetes, current state of the art treatment for foot ulcers and keeping pre-diabetes in check. Read more here.
REDDSTAR’s partner from University of Munich, Germany (Ludwig-Maximilians-Universität München, LMU-M) had a journal article published in Drug Discovery Today: Disease Models. LMU-M are working in the area of diabetic nephropathy and are examining how mesenchymal stromal cells may help. This new journal article focuses on animal models of kidney inflammation for drug development. The article is entitled Animal models of kidney inflammation in translational medicine. Read more here.
UNISTEM is an engaging pan-European event organised to stimulate thought and engage young people to see stem cell research and science as an exciting, humanitarian activity where big challenges in human health are addressed and the answers have yet to be discovered. Read more here.
REDDSTAR Dissemination Officer Danielle Nicholson interviewed Martin Ridderstråle: Vice President, Head of Clinic at Steno Diabetes Center in Copenhagen, Denmark to discuss his work and diabetes care in the context of REDDSTAR | Repair of Diabetic Damage by Stromal Cell Administration. Read more here.
In conjunction with our partner at Leiden University Medical Center, we organized the EU MSC2 2015, a meeting in Leiden, NL on September 7th and 8th to bring together nine EU-funded, mesenchymal stromal cell-focussed consortia. The two-day meeting brought together researchers from nine EU-funded projects pursuing MSC research, including: REDDSTAR, REACH, RETHRIM, Stellar, MERLIN, Nephstrom, SCIENCE, VISICORT and Adipoa-2. Read more here.
REDDSTAR’s Exploitation Workshop was held on 21 October in Porto. This workshop was planned as part of our ‘Description of Work’ to gain some external steering and advice at the two year mark in the project. ‘REDD6’ refers to the groups working on the six complications of diabetes explored through REDDSTAR- cardiomyopathy, foot ulceration, nephropathy, neuropathy, retinopathy and impaired fracture repair. The workshop invited all delegates to consider the future of the REDD6 network- both academic and commercial. Our external invited guests included Principal Investigator Dr Rafael Simo of CIBERDEM and Coordinator of EUROCONDOR; and Dr Rob Jones Executive Director and Company Secretary at Renasci in Nottingham. Read more here.
REDDSTAR Co-ordinator, Professor of Medicine Tim O’Brien NUI Galway, and Orbsen Therapeutics’ Head of Research, Dr. Steve Elliman took part in an interactive workshop during the International Society for Cellular Therapy (ISCT) 20th Anniversary meeting held in France at Le Palais des Congrès de Paris. The workshop showcased ‘EU-funded projects on Cellular Therapies’ and took place on Friday, 24 April 2014. Read more here.
In its eighth year (as of 2015), Debating Science Issues (DSI) is an All-Ireland science debating competition that encourages young people to engage in dialogue on the cultural, societal and ethical implications of advances in biomedical science. The programme of workshops, debates and STEM careers promotion was coordinated through REDDSTAR for the last two years. The eighth All-Ireland Finals of Debating Science Issues (DSI) took place on 29 April 2015 at the Royal College of Surgeons in Ireland, 123 St. Stephen’s Green, Dublin 1. Read more here.